Premiums and Cost-Sharing Features in Medicare's New Prescription Drug Program, 2006When Congress created the Medicare drug benefit in 2003, it also sought to generate more private plan options for senior and disabled beneficiaries in Medicare, with increased payments to attract sponsors and to support added benefits attractive to enrollees, especially…
Amid heightened public concern, the cost of prescription drugs is a focus of attention by the Biden administration and lawmakers in Congress and state capitals. Proposed actions range from allowing Medicare to negotiate the prices of certain drugs to limiting some drug price increases to inflation and capping out of pocket costs for Medicare beneficiaries in Part D, among other initiatives. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
Issue Brief See More
Related Prescription Drugs Resources
- Insulin Out-of-Pocket Costs in Medicare Part D
- Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020
- Out-of-pocket spending on insulin among people with private insurance
- How Do Prescription Drug Costs in the United States Compare to Other Countries?
- Public Opinion on Prescription Drugs and Their Prices
- Insulin Costs and Coverage in Medicare Part D
- Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
- The Public Weighs In On Medicare Drug Negotiations
- Potential Savings for Medicare Part D Enrollees Under Proposals to Add a Hard Cap on Out-of-Pocket Spending
- Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare Advantage
- 10 FAQs on Prescription Drug Importation
- Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
- Prescription Drug Rebates, Explained
- Who is most likely to have high prescription drug costs?
- Latest News on Prescription Drugs from Kaiser Health News
How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries?
The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
Issue Brief See More
- view as grid
- view as list
Health Affairs Article Examines Enrollment in Medicare Drug Plans As The Benefit Approaches Its Second Year
Health Affairs Article Examines Enrollment in Medicare Drug Plans As The Benefit Approaches Its Second YearAn article by Kaiser Family Foundation researchers published as a Health Affairs Web Exclusive provides a comprehensive look at the 2006 private Medicare drug plan enrollment as the enrollment period for 2007 begins. The article…
The 2006 Kaiser/Hewitt survey of large businesses that provide retiree health benefits to their workers assesses their evolving responses to the new Medicare drug benefit in 2006. It also looks at the rising costs and changing benefits of retiree health coverage overall in 2006, as well as the outlook for…
USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies
This poll, the third in a series conducted jointly by USA Today and public opinion researchers at the Kaiser Family Foundation and the Harvard School of Public Health, by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health finds Americans greatly value prescription drugs’ potential benefits…
Employer-provided health insurance is the primary source of insurance coverage in the United States, covering almost 160 million people or more than 90 percent of the non-elderly privately-insured population.1 In recent years, the percentage of firms who offer such benefits has been falling; 69 percent offered health coverage benefits in 2000,…
This data spotlight examines the availability of gap coverage in the private Medicare Part D drug plans offered to beneficiaries in 2011, the first year of the phase-out of the gap, as required under the 2010 health reform law. The changes for 2011 include a 50 percent discount on brand-name…
A 2-page issue brief that discusses significant trends in prescription drug coverage, expenditures, utilization, along with how the pharmaceutical industry prices drugs. The brief also looks at what states are doing to control drug costs and to address issues of affordability and access for low-income and elderly populations, how health…
Medicaid: Purchasing Prescription DrugsA policy brief explaining how Medicaid purchases outpatient drugs and outlining the policy tools available to states to limit the rate of growth in spending on prescription drugs. Policy Brief (28 pages)
This testimony was delivered by Tricia Neuman, a vice president of the Kaiser Family Foundation, at a Senate Finance Committee hearing on the Bush Administration's Proposals for Medicare Modernization. The statement, which draws upon a report prepared for the Foundation by Health Policy Alternatives, Inc., provides an overview of existing…
This policy brief describes Pharmacy Plus waivers being considered by some states for their Medicaid program and their implications for Medicaid financing. These waivers offer an opportunity for prescription drug coverage for low-income seniors, but they also include a major change in the financing of care for all seniors on…